Effect of renal impairment on the pharmacokinetics of prucalopride: A single-dose open-label Phase I study

Drug Design, Development and Therapy

Volumn 6, Issue , 2012, Pages 407-415

  Smith, William B ^a   Mannaert, Erik ^b   Verhaeghe, Tom ^b   Kerstens, René ^c   Vandeplassche, Lieve ^c   Van de Velde, Vera ^d  

^a UNIVERSITY OF TENNESSEE MEDICAL CENTER   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^c Movetis NV   (Belgium)

^d Independent Consultant Clinical Pharmacokinetics   (United States)

Author keywords

Pharmacokinetics; Prucalopride; Renal impairment; Safety

Indexed keywords

CREATININE; PRUCALOPRIDE;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIARRHEA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; FEMALE; HEART ARRHYTHMIA; HEART RATE; HUMAN; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; OPEN STUDY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BENZOFURANS; CASE-CONTROL STUDIES; CREATININE; FEMALE; HUMANS; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; SEROTONIN 5-HT4 RECEPTOR AGONISTS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84872301145     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S36142     Document Type: Article

References (9)

1. Resolor (prucalopride). Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/001012/WC500053998.pdf. Accessed March 26, 2012.
2. Frampton JE. Prucalopride. Drugs. 2009;69(17):2463-2476.
3. Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358(22):2344-2354.
4. Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfed with laxatives. Gut. 2009;58(3):357-365.
5. Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the effcacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation - a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009; 29(3):315-328.
6. Van de Velde V, Ausma J, Vandeplassche L. Pharmacokinetics of prucalopride (Resolor®) in man. Gut. 2008;Suppl 2:A282 (abstract).
7. Movetis. Prucalopride subjects with renal impairment. In: ClinicalTrials. gov [website on the Internet]. Bethesda, MD: US National Library of Medicine; 2012 [updated August 27, 2012]. Available from: http://clinicaltrials.gov/ct2/show/NCT01674192. NLM identifier: NCT01674192. Accessed September 22, 2012.
8. European Medicines Agency (EMEA). Note for Guidance on Good Clinical Practice. ICH harmonized tripartite guideline, CPMP/ ICH/135/95. London: EMEA; 2002. Available from: http://www.emea. europa.eu/pdfs/human/ich/013595en.pdf. Accessed June 11, 2012.
9. World Medical Association (WMA). WMA Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. Available from: http://www.wma.net/en/30publications/10policies/b3/. Accessed August 12, 2009.